Intrepid Financial Planning Group LLC Cuts Stock Position in Eli Lilly and Company (NYSE:LLY)

Intrepid Financial Planning Group LLC cut its position in Eli Lilly and Company (NYSE:LLY) by 0.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,278 shares of the company’s stock after selling 104 shares during the quarter. Eli Lilly and Company comprises 3.7% of Intrepid Financial Planning Group LLC’s holdings, making the stock its 6th biggest position. Intrepid Financial Planning Group LLC’s holdings in Eli Lilly and Company were worth $8,707,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Ninepoint Partners LP lifted its position in Eli Lilly and Company by 31.3% in the 4th quarter. Ninepoint Partners LP now owns 1,179 shares of the company’s stock valued at $910,000 after purchasing an additional 281 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in shares of Eli Lilly and Company by 12.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 47,311 shares of the company’s stock worth $36,524,000 after buying an additional 5,184 shares in the last quarter. Ascent Capital Management LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $373,000. one8zero8 LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $649,000. Finally, Diversified Enterprises LLC raised its position in shares of Eli Lilly and Company by 3.0% during the 4th quarter. Diversified Enterprises LLC now owns 4,066 shares of the company’s stock worth $3,139,000 after buying an additional 118 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have commented on LLY shares. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research report on Friday, January 17th. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Bank of America restated a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, March 6th. Finally, Citigroup lowered their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $1,009.72.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $813.55 on Friday. The firm’s 50 day simple moving average is $830.81 and its 200-day simple moving average is $843.24. The company has a market cap of $771.38 billion, a P/E ratio of 69.47, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its Board of Directors has approved a share buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.